IntRoductIon
Breast carcinoma represents the oncologic condition with the greatest morbidity and mortality among women worldwide, representing a quarter of all cancers in women 1 . Considering the great frequency of this disease, many studies were made for improving the accuracy of diagnostic, solutions for treatment, all aiming for a better survival and quality of life. Considering the latest guideline for the therapeutic management of breast carcinoma regarding the intrinsic molecular subtypes, treatment became much more personalized, and hormonotherapy and monoclonal antibody are usual in today's oncologic practice 2 . Considering all this progress, there are still a great number of deaths caused by breast carcinoma. The reasons vary from late presentation to medical service, the absence (in some countries, e.g. Romania) of a national screening program of breast malignancies 3 and also because in some particular type of cancers, such as bilateral breast carcinoma, no standardized therapeutic protocol is available 4 . Bilateral breast cancer is defined by the World Health Organization (WHO) as primary malignant lesions developed in each breast. They are considered synchronous if a contralateral breast carcinoma is diagnosed within 3 months after diagnosing the first tumor and are labeled as metachronous if more time passed 5 . Its frequency varies in clinical reports from 1.4% to 11.8% [6] [7] [8] [9] . Few statistics quantified how important a primary breast cancer is a risk factor for developing a contralateral breast cancer 10 , considering the side effects of neoadjuvant treatment, but its contribution is undoubtable 11 . Women that already have breast cancer are at two-to six-fold risk for developing another breast cancer in the contralateral breast, compared with the risk of developing a primary breast cancer in the general population 8 .
the objectIve of the study was to determine the histologic and immunohistochemical characteristics of patients with bilateral breast carcinoma admitted in a university emergency hospital.
mAteRIAls And methods
We collected our information for this retrospective series of cases from the Pathology Department of the University Emergency Hospital, Bucharest, Romania. All registered breast lesions from the 1 st of January 2015 to the 31 st of December 2017 in our department were pathologically evaluated. Patients' clinical data and medical history were obtained from our hospital database.
Pathological evaluation included the macroscopic registered data about tumor's dimensions and proximity to the surgical resection margins. The histologic specimens were fixed in 10% formalin and embalmed in paraffin blocks, 3-micrometers sections cut and usual stained hematoxylin and eosin. The WHO 4 th edition guidelines for breast pathology was used for assessing the histotype, grade of differentiation (according to Elston Ellis grading system) and TNM classification.
For each case, slides that contained well-preserved and representative tumor mass were chosen for immunohistochemistry tests. We used estrogen receptor antibody (SP1 clone, BioCare), progesterone receptor antibody (SP2 clone, BioCare) for the hormonal profile, Ki 67 (MIB-1, BioCare) as the nuclear antigen associated with cell proliferation and cerB-2/ HER2 oncoprotein (rabbit monoclonal antibody). Only nuclear staining was counted for ER, PR, and Ki-67; for HER2neu, the membranous staining was classified according to ASCO-CAP guidelines 2016. When recommended, in situ hybridization tests were completed in another laboratory, and we registered the final result (HER 2 amplified or not).
histologiques et moléculaires dans le contexte clinique obtenue à partir de notre base de données hospitalière. Résultats Tous les patients analysés étaient des femmes ménopausées. Le délai entre le diagnostic de la première et de la deuxième tumeur variait de 8 mois à 7 ans dans les cas métachrones. Conclusions Le carcinome mammaire bilatéral est une entité rare qui nécessite plus de paramètres histologiques pour être définie comme primaire ou mé-tastatique.
Mots-clés: cancer du sein, récepteurs hormonaux, tumeur du sein synchrone, mastectomie. the first and second tumor varied in metachronous cases from 8 months to 7 years. In the majority of cases, the bilateral breast lesions shared histologic, grading and hormone expression similarities. Conclusions Bilateral breast carcinoma is a rare entity that needs more histologic parameters to be defined as primary or metastatic.
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The evaluation of prognostic factors made possible to further classify tumors according to the St. Gallen consensus (2011) into molecular surrogate sub-types. Thereby, Luminal A cancers were hormone positive, HER2 negative and had a low proliferative index (Ki 67< 14%), Luminal B cancers were also hormone positive, but with a high mitotic index (Ki 67>14%) and/or HER2 positive. Non-luminal cancers were either HER2 enriched (did not express ER or PR) or triple negative (nor ER, PR or HER2 were positive).
All clinical data and histopathologic results were processed and analyzed using Microsoft Office Excel 2018. All the patients included in the study signed an informed consent according to the Helsinki agreement and the current national laws.
Results
A number of 354 breast tumors obtained by core biopsy, lumpectomy, quadrantectomies, modified mastectomy or mastectomy with lymph node dissection were evaluated, with benign diagnostic (most of them fibroadenomas and fibrocystic disease) or malignancies. 248 cases were carcinomas, most of them of no special type, about a quarter were of lobular type and sporadic cases of rare histotypes were also noted (Table 1) .
Considering the surrogate classification of molecular subtypes, the most frequent model met was Luminal B, followed by Luminal A (Figure 1 ). Few cases were of non-luminal type.
We selected the patients who were surgically treated for malignancy in both breasts. During the evaluated time, we found 6 patients, representing 4.83% of the total investigated cases. A synthetic presentation is easy to appreciate in Table 2 . Analyzed separately from synchronous breast carcinomas, in metachronous cases the median time-lapse until the diagnosis of the second breast malignancy was 9.9 months, with a range of variation from 8 months to 7 years.
In this brief analysis, we will underline the most important particularities of synchronous and metachronous breast carcinomas separately.
For synchronous bilateral breast carcinoma, in one case of three, the lesion was of low dimensions, diagnosed on a routine mammography evaluation and Another patient is quite similar to the first presented case, but with some individualities. In the right breast, there were multiple NST tumors, each of them with a moderate grade of differentiation (G2), none of them larger than 1.8 cm. Also, 1 of 8 examined lymph nodes presented metastasis. The contralateral breast had a single well differentiated (G1) tumor of NST histotype, with no affected locoregional lymph node. According to prognostic factors immunohistochemically acquired, we classified all tumors from both breasts of luminal A type. The elected surgical treatment was also bilateral mastectomy with lymph node dissections.
In contrast with the anterior presented cases, the third one had a stage IIIB breast bilateral carcinoma. Considering the emergency profile of our hospital, the patient presented an ulcerated bleeding breast mass. The clinical and imaging examination evaluated both breasts and noticed malignant features bilaterally. An emergency mastectomy was performed, and a biopsy was obtained from the contralateral breast. The diagnosis in both, mastectomy specimen and biopsy, was NST G2, of Luminal A profile (Figure 2) . No in situ component was found, but tumoral emboli, perineural invasion and skin ulceration by tumoral proliferation were noticed ( Figure 3A and 3B) . No additional pathologic information about lymph node invasion was obtained.
The metachronous cases we found are about to be debated considering their primitive or metastatic origin. In 2 of 3 patients, they were in advanced stages of disease (stage IV), with distant metastases (with pulmonary propensity in both cases). We did not find significant differences in histotype (in both patients, bilateral NST), or in molecular profile (both Luminal B and HER2 negative) but the grade of differentiation was not the same, in the second diagnosed tumor being higher (Table 2) . No in situ component was identified, in first or second diagnosed breast affected by cancer. A particular aspect was the benign associated lesions that we found. Fibroadenomas coexisted with fibrocystic breast disease and NST carcinoma in both breasts ( Figure 3C and 3D) .
A single case presented with a history of in situ carcinoma treated with mastectomy and local radiotherapy. After 7 years, in the contralateral breast, an adenosquamous carcinoma developed.
From the clinical point of view, all cases were postmenopausal women, 5 of 6 patients were overweight and hypertensive; half of them had imbalanced thyroid function; 2 of them associated usual gynecological pathology (cervicitis, uterine leiomyomas) and half of them came from the rural area. The median diameter of tumors was 2.3 cm, with a variation ranging from 0.8 to 3.4 cm.
dIscussIon
To distinguish the synchronous from metachronous bilateral breast cancer, we used the WHO 4 th edition guideline cutoff of 3 months interval between diagnosing the first and the contralateral breast tumor. Even in the literature, no consensus about the outcome of bilateral breast carcinoma compared to unilateral ones, most of them suggest a poor survival, in particular for women affected by synchronous breast carcinomas [12] [13] [14] [15] . Considering the molecular subtype, the majority of our cases were of luminal type, meaning that were expressing hormonal receptors. The higher prevalence of hormonal receptor positive bilateral breast Age at Diagnostic  66  67  54  61  60  62  84  84  48  48  50  50  Tumoral Stage  IV  IV  0  IIA  IV  IV  IIIB  biopsy  IIB  IA  Ia  Ia  Grade and Histotype  NST G2  NST G2  IDC  Adenosquamous  NST G1  NST G3  NST G2  NST G2  NST G2  NST G1  NST G1  NST G1 carcinomas was similar to other studies 16 . In the literature, it is noticed that the elevated risk of a second malignancy of breast cancer survivals is related to hormonal receptor status 17, 18 . The similarities in histologic appearance and hormone receptor positivity in the same patient could be an argument for the hypothesis that tumors arise from a common circumstance and their subtypes are predetermined in the early stage of breast cancer development 19, 20 .
A more problematic aspect was to distinguish a bilateral breast cancer from a contralateral metastatic spread. The second tumor, in the absence of local, regional or distant metastasis, it is compatible with a second primary cancer 9, 21 . Otherwise, in common histologic terms, it is impossible to do this differentiation 22, 23 . We searched the literature and we found various criteria [24] [25] [26] , none being approved as a golden standard. Despite innovative diagnostic methods, such as cDNA microarray-based CGH, the most used is the Chaudaty et al proposal, elaborated in 1984 21 . This study stipulates that a bilateral breast carcinoma, comparative to a metastatic one, riches the following criteria: a). the presence of in situ changes in the contralateral tumor b). histologic differences between the first tumor and the contralateral one c). the degree of histologic differentiation of the tumor in the second breast is distinctly greater than that of the lesion in the first breast and d). no evidence of local, regional or distant metastasis from cancer in the ipsilateral breast.
Our presented cases do not fulfill all the Chaudaty criteria, but clinical and histological aspects made us think that metastatic disease is less probable. In the synchronous bilateral breast carcinoma, considering the incipient disease, the absence of vascular and perineural tumor invasion, we presumed that tumors are both primaries. We believe the same for the patient with a history of in situ ductal carcinoma and contralateral adenosquamous carcinoma. The problematic aspects are in patients with stage 4 disease, where it is difficult to establish the primary or metastatic nature of the lesion. Considering the severity of disease, in this point of medical knowledge, the distinction would bring no clinical utility.
An interesting point represents the association in one case of bilateral fibroadenoma, that, according to Dupont and al, could be a risk factor for malignancies 27 . A clinical aspect that is further to be investigated is the strong correlation between hypertension and thyroid function. Several articles observed a connection between benign or malignant breast disease and thyroid dysfunction [28] [29] [30] , and the majority of cases correlated with a lower thyroid function 31 . Considering hypertension, there are studies about this correlation, some of them with astonishing results, considering that the risk of a hypertensive woman for developing a breast carcinoma is up to 15% higher compared to general population 32, 33 .
conclusIons Although bilateral breast carcinomas are rare cases, their early diagnosis is mandatory. In non-metastatic diseases, we have found important similarities in tumors' histology and hormonal profile in both breasts, so, an accurate distinction between primary or metastatic disease is not possible using only histopathologic examinations. Also, the longtime risk of metachronous breast cancer confirms the importance of mammographic follow up of ipsi-and contralateral breast of patients already treated of breast cancer 34 .
